Latest Biotech News

BioNTech disclosed positive Phase 2 results for trastuzumab pamirtecan (BNT323), setting the stage for an FDA filing as the company looks to compete in HER2-positive oncology where antibody-drug...

GSK said it plans to start five Phase 3 studies for a gynecological cancer antibody-drug conjugate licensed from Hansoh Pharma after early promising data. The company’s decision expands the trial...

Sidewinder Therapeutics raised $137 million in a Series B to advance a pipeline of bispecific antibody-drug conjugates aimed at improving tumor targeting and safety. The round was co-led by...

Neomorph raised an additional $100 million in funding to advance molecular glue programs, expanding resources for discovery and translation of degradation-oriented therapeutics. The company’s...

AbbVie agreed to license ex-China rights to two Haisco Pharmaceutical pain compounds in a transaction structured around a $30 million upfront payment for the candidates. The licensing arrangement...

Vivatides Therapeutics closed an oversubscribed $54 million Series A to advance extrahepatic RNA therapeutics, focusing on improvements to delivery technologies and preclinical optimization. The...

Seaport Therapeutics and Hemab Therapeutics moved toward public markets as the biotech IPO window shows signs of reopening, each filing for IPO plans to fund clinical and pipeline work. Seaport...

Spyre Therapeutics reported early Phase 2 data for SPY001 in ulcerative colitis, meeting the study’s primary goal and supporting further development as the company aims to compete with entrenched...

Revolution Medicines reported phase 3 success for its investigational KRAS inhibitor daraxonrasib in metastatic pancreatic cancer, extending survival versus chemotherapy in a registrational...

Ideaya Biosciences reported that its uveal melanoma program cleared an internal success benchmark in a late-stage open-label trial. The company said the results strengthen expectations for an...

Allogene Therapeutics said its off-the-shelf CAR-T, cema-cel, achieved an interim goal in an ongoing phase 3 trial in B-cell lymphoma. In the interim analysis, 58% of treated patients reached...

GSK said it plans five phase 3 studies for an antibody-drug conjugate licensed from Hansoh Pharma after early promising data. The company’s move expands the late-stage footprint for a gynecologic...

Final overall survival results from the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel reduced the risk of death versus nab-paclitaxel alone in platinum-resistant ovarian...

Spyre Therapeutics reported early phase 2 results supporting its ulcerative colitis monoclonal antibody approach. In its SKYLINE study, subjects taking SPY001 met the primary safety goal and...

Sidewinder Therapeutics secured a $137 million Series B to advance a pipeline of bispecific antibody-drug conjugates targeting cancer. The funding is co-led by Frazier Life Sciences and the...

Labcorp and Children’s Hospital of Philadelphia (CHOP) announced plans to develop and commercialize specialty pediatric diagnostics. The collaboration is designed to move tests across areas...

AbbVie agreed to pay Chinese biotech Haisco $30 million upfront for two non-opioid acute pain candidates, part of a deal described at up to $745 million. The transaction expands AbbVie’s pain...

Regeneron entered radiopharmaceutical expansion through a $2.1 billion biobucks pact with Telix. The agreement ties into Regeneron’s shifting growth strategy as its obesity program activity and...

GSK is moving an antibody-drug conjugate licensed from Hansoh Pharma into an expanded late-stage development plan after early data signaled potential in gynecological cancers. The company said it...

Final overall survival data from the Phase 3 ROSELLA trial show that relacorilant (Lifyorli) added to nab-paclitaxel significantly improves outcomes in platinum-resistant ovarian cancer. At the...